Harrow Health, Inc.
HROW
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.4B
$38.54
▲ +0.73%
P/E
-38.78
Mkt Cap
$1.4B
52-Wk Range
$28.54–$54.85
52-Week Range
$28.54 - $54.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 3.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized expertise in ophthalmology with established ImprimisRx compounding platform
- Diversified revenue model combining core operations with high-growth equity investments
- Royalty rights providing passive income streams from multiple clinical-stage drug candidates
- Strategic positioning in high-demand therapeutic areas including ocular surface diseases and sedation
- Established relationships with eye care professionals and healthcare providers
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Moderate growth ahead
Expansion of ImprimisRx compounding services and market penetration in ophthalmology
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Strong
+16.4% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying HROW right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.46 vs -$0.18 consensus (-157.3% surprise). Revenue of $70.7M vs $69.8M expected (+1.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-157.3%
Revenue trend · last 8Q
—
+84%
+38%
+30%
+45%
+33%
-8%
+11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$49.3M
$66.8M
$47.8M
$63.7M
$71.6M
$89.1M
$44.2M
$70.7M
Margins · last 8Q
Gross
71.3%
Operating
-15.6%
Profit
-24.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · $88.00 · May 13, 2026
vs Industry
How HROW stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related